Koru Medical price target raised to $4 from $3 at Canaccord

Canaccord raised the firm’s price target on Koru Medical (KRMD) to $4 from $3 and keeps a Buy rating on the shares. The firm said this was the company’s third consecutive quarter of double digit growth with strength in its domestic core business as they continues to outpace the US core SCIg market while it grew nearly 300% in its Novel Therapies business given clinical trial orders and NRE milestone progress.